David Dai
Stock Analyst at UBS
(2.23)
# 2,838
Out of 5,090 analysts
31
Total ratings
48.15%
Success rate
-1.71%
Average return
Main Sectors:
Top Industries:
Stocks Rated by David Dai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CATX Perspective Therapeutics | Maintains: Buy | $18 → $7 | $2.39 | +192.89% | 2 | Nov 21, 2025 | |
| KURA Kura Oncology | Maintains: Buy | $14 → $16 | $12.02 | +33.11% | 3 | Nov 14, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $115 → $117 | $95.99 | +21.89% | 1 | Nov 6, 2025 | |
| SNDX Syndax Pharmaceuticals | Maintains: Buy | $35 → $38 | $19.75 | +92.45% | 3 | Nov 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $114 → $132 | $107.05 | +23.31% | 3 | Oct 31, 2025 | |
| MRUS Merus | Downgrades: Neutral | $72 → $97 | $96.20 | +0.83% | 2 | Sep 30, 2025 | |
| TLX Telix Pharmaceuticals | Maintains: Buy | $23 → $20 | $9.74 | +105.34% | 1 | Sep 23, 2025 | |
| NRIX Nurix Therapeutics | Maintains: Buy | $30 → $26 | $18.00 | +44.44% | 2 | Jul 10, 2025 | |
| SMMT Summit Therapeutics | Initiates: Buy | $30 | $18.83 | +59.36% | 1 | Jul 1, 2025 | |
| IOVA Iovance Biotherapeutics | Downgrades: Neutral | $17 → $2 | $2.22 | -9.91% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $24 | $10.59 | +126.63% | 2 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $24 | $40.24 | -40.36% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $69 | $16.38 | +321.25% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $35.95 | +39.08% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $44.95 | +33.48% | 1 | Oct 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $28 | $0.56 | +4,858.38% | 1 | Mar 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $86.35 | -53.68% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $1.38 | +2,798.55% | 1 | Feb 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $1.85 | +2,602.70% | 1 | Nov 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $41 → $52 | $29.75 | +74.82% | 1 | Mar 17, 2020 |
Perspective Therapeutics
Nov 21, 2025
Maintains: Buy
Price Target: $18 → $7
Current: $2.39
Upside: +192.89%
Kura Oncology
Nov 14, 2025
Maintains: Buy
Price Target: $14 → $16
Current: $12.02
Upside: +33.11%
BioNTech SE
Nov 6, 2025
Maintains: Neutral
Price Target: $115 → $117
Current: $95.99
Upside: +21.89%
Syndax Pharmaceuticals
Nov 4, 2025
Maintains: Buy
Price Target: $35 → $38
Current: $19.75
Upside: +92.45%
Nuvalent
Oct 31, 2025
Maintains: Buy
Price Target: $114 → $132
Current: $107.05
Upside: +23.31%
Merus
Sep 30, 2025
Downgrades: Neutral
Price Target: $72 → $97
Current: $96.20
Upside: +0.83%
Telix Pharmaceuticals
Sep 23, 2025
Maintains: Buy
Price Target: $23 → $20
Current: $9.74
Upside: +105.34%
Nurix Therapeutics
Jul 10, 2025
Maintains: Buy
Price Target: $30 → $26
Current: $18.00
Upside: +44.44%
Summit Therapeutics
Jul 1, 2025
Initiates: Buy
Price Target: $30
Current: $18.83
Upside: +59.36%
Iovance Biotherapeutics
May 16, 2025
Downgrades: Neutral
Price Target: $17 → $2
Current: $2.22
Upside: -9.91%
May 12, 2025
Maintains: Buy
Price Target: $30 → $24
Current: $10.59
Upside: +126.63%
Oct 24, 2024
Initiates: Sell
Price Target: $24
Current: $40.24
Upside: -40.36%
Oct 24, 2024
Initiates: Buy
Price Target: $69
Current: $16.38
Upside: +321.25%
Oct 24, 2024
Initiates: Buy
Price Target: $50
Current: $35.95
Upside: +39.08%
Oct 24, 2024
Initiates: Buy
Price Target: $60
Current: $44.95
Upside: +33.48%
Mar 31, 2022
Initiates: Outperform
Price Target: $28
Current: $0.56
Upside: +4,858.38%
Mar 16, 2022
Initiates: Outperform
Price Target: $40
Current: $86.35
Upside: -53.68%
Feb 4, 2022
Initiates: Outperform
Price Target: $40
Current: $1.38
Upside: +2,798.55%
Nov 18, 2021
Initiates: Outperform
Price Target: $50
Current: $1.85
Upside: +2,602.70%
Mar 17, 2020
Upgrades: Outperform
Price Target: $41 → $52
Current: $29.75
Upside: +74.82%